180 related articles for article (PubMed ID: 22978415)
1. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L.
Basavapathruni A; Jin L; Daigle SR; Majer CR; Therkelsen CA; Wigle TJ; Kuntz KW; Chesworth R; Pollock RM; Scott MP; Moyer MP; Richon VM; Copeland RA; Olhava EJ
Chem Biol Drug Des; 2012 Dec; 80(6):971-80. PubMed ID: 22978415
[TBL] [Abstract][Full Text] [Related]
2. Regulation of Wnt signaling target gene expression by the histone methyltransferase DOT1L.
Gibbons GS; Owens SR; Fearon ER; Nikolovska-Coleska Z
ACS Chem Biol; 2015 Jan; 10(1):109-14. PubMed ID: 25361163
[TBL] [Abstract][Full Text] [Related]
3. A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
Anglin JL; Song Y
J Med Chem; 2013 Nov; 56(22):8972-83. PubMed ID: 23879463
[TBL] [Abstract][Full Text] [Related]
4. Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development.
Barry ER; Corry GN; Rasmussen TP
Expert Opin Ther Targets; 2010 Apr; 14(4):405-18. PubMed ID: 20230194
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L.
Anglin JL; Deng L; Yao Y; Cai G; Liu Z; Jiang H; Cheng G; Chen P; Dong S; Song Y
J Med Chem; 2012 Sep; 55(18):8066-74. PubMed ID: 22924785
[TBL] [Abstract][Full Text] [Related]
6. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
Daigle SR; Olhava EJ; Therkelsen CA; Majer CR; Sneeringer CJ; Song J; Johnston LD; Scott MP; Smith JJ; Xiao Y; Jin L; Kuntz KW; Chesworth R; Moyer MP; Bernt KM; Tseng JC; Kung AL; Armstrong SA; Copeland RA; Richon VM; Pollock RM
Cancer Cell; 2011 Jul; 20(1):53-65. PubMed ID: 21741596
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent DOT1L inhibitors by AlphaLISA based High Throughput Screening assay.
Song Y; Li L; Chen Y; Liu J; Xiao S; Lian F; Zhang N; Ding H; Zhang Y; Chen K; Jiang H; Zhang C; Liu YC; Chen S; Luo C
Bioorg Med Chem; 2018 May; 26(8):1751-1758. PubMed ID: 29534934
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and anti leukemia cells proliferation activities of pyrimidylaminoquinoline derivatives as DOT1L inhibitors.
Zhang L; Chen Y; Liu N; Li L; Xiao S; Li X; Chen K; Luo C; Chen S; Chen H
Bioorg Chem; 2018 Oct; 80():649-654. PubMed ID: 30059890
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies.
Yao Y; Chen P; Diao J; Cheng G; Deng L; Anglin JL; Prasad BV; Song Y
J Am Chem Soc; 2011 Oct; 133(42):16746-9. PubMed ID: 21936531
[TBL] [Abstract][Full Text] [Related]
10. The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79.
Chen S; Yang Z; Wilkinson AW; Deshpande AJ; Sidoli S; Krajewski K; Strahl BD; Garcia BA; Armstrong SA; Patel DJ; Gozani O
Mol Cell; 2015 Oct; 60(2):319-27. PubMed ID: 26439302
[TBL] [Abstract][Full Text] [Related]
11. Novel DOT1L ReceptorNatural Inhibitors Involved in Mixed Lineage Leukemia: a Virtual Screening, Molecular Docking and Dynamics Simulation Study.
Raj U; Kumar H; Gupta S; Varadwaj PK
Asian Pac J Cancer Prev; 2015; 16(9):3817-25. PubMed ID: 25987043
[TBL] [Abstract][Full Text] [Related]
12. Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia.
Barve A; Vega A; Shah PP; Ghare S; Casson L; Wunderlich M; Siskind LJ; Beverly LJ
Cells; 2019 Oct; 8(11):. PubMed ID: 31717699
[TBL] [Abstract][Full Text] [Related]
13. Structure-guided DOT1L probe optimization by label-free ligand displacement.
Yi JS; Federation AJ; Qi J; Dhe-Paganon S; Hadler M; Xu X; St Pierre R; Varca AC; Wu L; Marineau JJ; Smith WB; Souza A; Chory EJ; Armstrong SA; Bradner JE
ACS Chem Biol; 2015 Mar; 10(3):667-74. PubMed ID: 25397901
[TBL] [Abstract][Full Text] [Related]
14. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
Daigle SR; Olhava EJ; Therkelsen CA; Basavapathruni A; Jin L; Boriack-Sjodin PA; Allain CJ; Klaus CR; Raimondi A; Scott MP; Waters NJ; Chesworth R; Moyer MP; Copeland RA; Richon VM; Pollock RM
Blood; 2013 Aug; 122(6):1017-25. PubMed ID: 23801631
[TBL] [Abstract][Full Text] [Related]
15. Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches.
Sabatino M; Rotili D; Patsilinakos A; Forgione M; Tomaselli D; Alby F; Arimondo PB; Mai A; Ragno R
J Comput Aided Mol Des; 2018 Mar; 32(3):435-458. PubMed ID: 29335872
[TBL] [Abstract][Full Text] [Related]
16. Catalytic properties and kinetic mechanism of human recombinant Lys-9 histone H3 methyltransferase SUV39H1: participation of the chromodomain in enzymatic catalysis.
Chin HG; Patnaik D; Estève PO; Jacobsen SE; Pradhan S
Biochemistry; 2006 Mar; 45(10):3272-84. PubMed ID: 16519522
[TBL] [Abstract][Full Text] [Related]
17. In Situ Proteome Profiling and Bioimaging Applications of Small-Molecule Affinity-Based Probes Derived From DOT1L Inhibitors.
Zhu B; Zhang H; Pan S; Wang C; Ge J; Lee JS; Yao SQ
Chemistry; 2016 Jun; 22(23):7824-36. PubMed ID: 27115831
[TBL] [Abstract][Full Text] [Related]
18. Nucleoside and Non-Nucleoside DOT1L Inhibitors: Dawn of MLLrearranged Leukemia.
Cao M; Li T; Chen Y; Zhai X
Mini Rev Med Chem; 2021; 21(11):1337-1350. PubMed ID: 33430727
[TBL] [Abstract][Full Text] [Related]
19. The upstreams and downstreams of H3K79 methylation by DOT1L.
Vlaming H; van Leeuwen F
Chromosoma; 2016 Sep; 125(4):593-605. PubMed ID: 26728620
[TBL] [Abstract][Full Text] [Related]
20. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias.
Yi Y; Ge S
J Hematol Oncol; 2022 Mar; 15(1):35. PubMed ID: 35331314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]